Roche is buying Promedior to obtain its entire medical portfolio. Promedior’s leading drug candidate is designed to treat idiopathic pulmonary fibrosis, a disease for which only two drugs are approved to treat, one of which is made by Roche.
Under the deal, Roche will pay Promedior another $1 billion if its drug development program meets goals for approval and marketing, according to The Boston Globe.
Bristol-Myers Squibb had a similar deal with Promedior in 2015, but decided last year not to buy the company.
Read the full article here.
More articles on pharmacy:
Drugmakers could lose $1T in sales and still be most profitable industry, analysis finds
CAR-T costs ‘not sustainable’ for hospitals, researchers say
How Walgreens, CVS see the future of pharmacy
